Doctors say active monitoring, hormone therapy and newer focal treatments are reshaping care decisions for men.

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS compared to EBRT boost.

Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk prostate cancer.

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that returned after radiotherapy. Matched analyses estimated 10-year ...

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...

"We found that preexisting depression was associated with a 2.5-fold increase in mortality risk for patients with PCa, highlighting its role in exacerbating disease progression and worsening survival.

In India, awareness about prostate cancer remains alarmingly low, with many men avoiding screenings altogether and dismissing early warning signs until the disease has progressed. This reluctance ...

About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.

Prostate cancer rates have risen in recent years, with a sharp increase in cases diagnosed in advanced stages, the American Cancer Society said Tuesday. Diagnoses of prostate cancer rose 3% annually ...